Physician profile
William Kosmala
NPI 1760442511
$3,395.85
in general payments reported to CMS, 2019-2025
28 companies · $747 in 2025
The $747 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $122 · 2021: $404 · 2022: $614 · 2023: $490 · 2024: $302 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,516 · Education: $23.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.75 |
| Education | $23.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $995.06 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $451.32 | 2019-2025 | Tremfya |
| Nestle Healthcare Nutrition INC. | $340.43 | 2021-2023 | |
| Abbvie INC. | $294.35 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $292.90 | 2019-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $100.91 | 2024-2025 | Voquezna |
| Pfizer INC. | $89.05 | 2019-2025 | |
| Celltrion USA INC. | $85.90 | 2024-2025 | Vegzelma, Zymfentra |
| Ardelyx, INC. | $80.59 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $69.56 | 2023-2025 | |
| Madrigal Pharmaceuticals | $59.59 | 2024-2025 | Resmetirom, Rezdiffra |
| Merck Sharp & Dohme LLC | $58.76 | 2019-2023 | Dificid |
| Ferring Pharmaceuticals INC. | $55.97 | 2019 | |
| Vivus LLC | $54.62 | 2022-2023 | Pancreaze |
| Celgene Corporation | $51.21 | 2021-2023 | Zeposia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $43.03 | 2019-2023 | Sutab |
| Lilly USA, LLC | $37.19 | 2024-2025 | Omvoh |
| Allergan, INC. | $35.53 | 2019 | |
| Clovis Oncology, INC. | $34.56 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.81 | 2025 | Dupixent |
| Mirum Pharmaceuticals, INC. | $25.00 | 2025 | Livmarli |
| Pacira Pharmaceuticals Incorporated | $22.79 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.06 | 2019 | |
| Boston Scientific Corporation | $18.96 | 2020 | |
| Inspire Medical Systems, INC. | $18.69 | 2025 | Inspire |
| Evoke Pharma, INC. | $13.29 | 2023 | Gimoti |
| Novartis Pharmaceuticals Corporation | $12.72 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$41,390.12 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kosmala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.